Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial: 6.5-study year follow-up data

被引：0

作者：

Wolinsky, J. S. ^{[1
]}

Brochet, B. ^{[2
]}

Hartung, H. -P. ^{[3
,4
]}

Naismith, R. T. ^{[5
]}

Airas, L. ^{[6
]}

Coutant, K. ^{[7
]}

Koendgen, H. ^{[7
]}

Manfrini, M. ^{[7
]}

Mehta, L. ^{[8
]}

Prajapati, K. ^{[9
]}

Kappos, L. ^{[10
]}

机构：

[1] McGovern Med Sch, Houston, TX USA

[2] Univ Bordeaux, Bordeaux, France

[3] Heinrich Heine Univ Dusseldorf, Ctr Neurol & Neuropsychiat, Dusseldorf, Germany

[4] Heinrich Heine Univ Dusseldorf, LVR Klinikum, Dusseldorf, Germany

[5] Washington Univ, Sch Med, St Louis, MO USA

[6] Univ Turku, Div Clin Neurosci, Turku, Finland

[7] F Hoffmann La Roche Ltd, Basel, Switzerland

[8] Genentech Inc, San Francisco, CA 94080 USA

[9] GCE Solut Inc, Amsterdam, Netherlands

[10] Univ Hosp Basel, Basel, Switzerland

来源：

MULTIPLE SCLEROSIS JOURNAL | 2019年 / 25卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

159

引用

页码：56 / 57

页数：2

共 34 条

[31] A multicentre, open label, single-arm, phase 3b study (CONSONANCE) to assess the effectiveness and safety of ocrelizumab in patients with primary and secondary progressive multiple sclerosis: year-1 interim analysis (P1-1.Virtual)
Comi, Giancarlo
Bermel, Robert
Bar-Or, Amit
McGinley, Marisa
Arnold, Douglas
Henry, Roland
Benedict, Ralph
Bhargava, Pavan
Butzkueven, Helmut
Chard, Declan
Gherardi, Guy
Howell, Owain
Lebrun-Frenay, Christine
Leocani, Letizia
Kazlauskaite, Agne
Kuenzel, Thomas
Montalban, Xavier
Sormani, Maria Pia
Sellebjerg, Finn
Craveiro, Licinio
Lubetzki, Catherine
NEUROLOGY, 2022, 98 (18)
[32] 2-year follow-up from JAVELIN Lung 200, an open-label, randomized, phase 3 study of avelumab vs docetaxel in patients with platinum-treated advanced non-small cell lung cancer (NSCLC)
Barlesi, Fabrice
Ozguroglu, Mustafa
Vansteenkiste, Johan
Spigel, David
Yang, James
Ishii, Hidenobu
Garassino, Marina
de Marinis, Filippo
Szczesna, Aleksandra
Polychronis, Andreas
Uslu, Ruchan
Krzakowski, Maciej
Lee, Jong-Seok
Calabro, Luana
Aren Frontera, Osvaldo
Ellers-Lenz, Barbara
Bajars, Marcis
Ruisi, Mary
Park, Keunchil
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
[33] ELOQUENT-2 Update: A Phase 3, Randomized, Open-Label Study of Elotuzumab in Combination with Lenalidomide/Dexamethasone (ELd) vs Lenalidomide/Dexamethasone (Ld) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)-3-Year Safety and Efficacy Follow-up
Dimopoulos, M.
Lonial, S.
White, D.
Moreau, P.
Palumbo, A.
San Miguel, J.
Shpilberg, O.
Anderson, K.
Grosicki, S.
Spicka, I.
Walter-Croneck, A.
Magen-Nativ, H.
Mateos, M. -V
Belch, A.
Reece, D.
Beksac, M.
Bleickardt, E.
Poulart, V.
Katz, J.
Singhal, A. K.
Richardson, P.
ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 122 - 123
[34] Long-Term Efficacy of Reduced-Intensity Conditioning Compared to Standard Myeloablative Conditioning before Allogeneic Hemopoietic Cell Transplantation in Patients with Acute Myeloid Leukemia in First Complete Remission: 10-Year Follow-up of a Prospective, Open-Label Randomized Phase III Trial
Fasslrinner, Frederick
Schetelig, Johannes
Burchert, Andreas
Kramer, Michael
Trenschel, Rudolf
Hegenbart, Ute
Stadler, Michael
Schafer-Eckart, Kerstin
Batzel, Michael
Eich, Hans
Engenhart-Cabillic, Rita
Krause, Mechthild
Dreger, Peter
Neubauer, Andreas
Ehninger, Gerhard
Beelen, Dietrich W.
Berdel, Wolfgang E.
Siepmann, Timo
Stelljes, Matthias
Bornhauser, Martin
BLOOD, 2017, 130

← 1 2 3 4 →